drugset / Trial / NCT06104215
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
Phase 0
Recruiting
14 enrolled
The Affiliated Hospital of Xuzhou Medical University
Guangzhou Bioresette Biomedical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.
Timeline
- Start
- 2023-10-22
- Primary completion
- 2026-10-20
- Completion
- 2027-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGT007H Injection | Cell therapy | 2e+08 cells | Intravenous |
| Subject | BGT007H Injection | Cell therapy | 5e+08 cells | Intravenous |
| Subject | BGT007H Injection | Cell therapy | 1e+09 cells | Intravenous |
| Subject | BGT007H Injection | Cell therapy | 3e+09 cells | Intravenous |
| Subject | BGT007H Injection | Cell therapy | 6e+09 cells | Intravenous |